Synthesis, optimization and structure-activity relationships of 3,5-disubstituted isoxazolines as new anti-tuberculosis agents.

[1]  B. Meibohm,et al.  Discovery of novel isoxazolines as anti-tuberculosis agents. , 2007, Bioorganic & medicinal chemistry letters.

[2]  M. Spigelman,et al.  New tuberculosis therapeutics: a growing pipeline. , 2007, The Journal of infectious diseases.

[3]  P. Menéndez,et al.  The contribution of oxazolidinone frame to the biological activity of pharmaceutical drugs and natural products. , 2007, Mini reviews in medicinal chemistry.

[4]  Richard E. Lee,et al.  Nitrofurans as novel anti-tuberculosis agents: identification, development and evaluation. , 2007, Current topics in medicinal chemistry.

[5]  M. Matsumoto,et al.  Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. , 2006, Journal of medicinal chemistry.

[6]  R. Sood,et al.  Antimycobacterial activities of oxazolidinones: a review. , 2006, Infectious disorders drug targets.

[7]  A. Renslo,et al.  Recent developments in the identification of novel oxazolidinone antibacterial agents. , 2006, Bioorganic & medicinal chemistry.

[8]  A. Lenaerts,et al.  Synthesis of new and potent analogues of anti-tuberculosis agent 5-nitro-furan-2-carboxylic acid 4-(4-benzyl-piperazin-1-yl)-benzylamide with improved bioavailability. , 2006, Bioorganic & medicinal chemistry letters.

[9]  A. Lenaerts,et al.  Synthesis and evaluation of cyclic secondary amine substituted phenyl and benzyl nitrofuranyl amides as novel antituberculosis agents. , 2005, Journal of medicinal chemistry.

[10]  P. Martín-Dávila,et al.  Linezolid for the treatment of multidrug-resistant tuberculosis. , 2005, The Journal of antimicrobial chemotherapy.

[11]  K. Hevener,et al.  Synthesis and evaluation of nitrofuranylamides as novel antituberculosis agents. , 2004, Journal of medicinal chemistry.

[12]  Marianne Terrot,et al.  Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. , 2003, Journal of combinatorial chemistry.

[13]  W. Burman,et al.  Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. , 2001, American journal of respiratory and critical care medicine.

[14]  Christopher Dye,et al.  Global burden of tuberculosis , 1999 .

[15]  C. Dye,et al.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.

[16]  J. Murray.  Tuberculosis and HIV Infection: A Global Perspective , 1998, Respiration.

[17]  S. Buchwald,et al.  A Simple Catalytic Method for the Conversion of Aryl Bromides to Arylamines , 1995 .

[18]  T. J. Nitz,et al.  Picornavirus inhibitors: trifluoromethyl substitution provides a global protective effect against hepatic metabolism. , 1995, Journal of medicinal chemistry.

[19]  A. Padwa.  1,3-Dipolar Cycloaddition Chemistry , 1984 .

[20]  James C. Sacchettini,et al.  Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis , 2008, Nature Reviews Microbiology.

[21]  B. Bloom,et al.  Tuberculosis Pathogenesis, Protection, and Control , 1994 .